ProCE Banner Activity

Phase II Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-threatening Acute GVHD

Slideset Download
Conference Coverage
Urinary-derived human chorionic gonadotropin/epidermal growth factor appears safe, well-tolerated, and efficacious in addition to immunosuppressive therapy for patients with life-threatening acute graft-vs-host disease.

Released: December 16, 2021

Expiration: December 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation